Bausch Health Companies (BHC) Competitors

$6.77
-0.30 (-4.24%)
(As of 05/17/2024 08:53 PM ET)

BHC vs. MLTX, MRUS, MRVI, JANX, RYTM, DYN, FOLD, RNA, ACAD, and MOR

Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Maravai LifeSciences (MRVI), Janux Therapeutics (JANX), Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), Amicus Therapeutics (FOLD), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.

Bausch Health Companies vs.

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

MoonLake Immunotherapeutics presently has a consensus price target of $74.46, suggesting a potential upside of 87.32%. Bausch Health Companies has a consensus price target of $11.33, suggesting a potential upside of 67.41%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Bausch Health Companies received 303 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 77.42% of users gave MoonLake Immunotherapeutics an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.

CompanyUnderperformOutperform
MoonLake ImmunotherapeuticsOutperform Votes
48
77.42%
Underperform Votes
14
22.58%
Bausch Health CompaniesOutperform Votes
351
61.90%
Underperform Votes
216
38.10%

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Bausch Health Companies. MarketBeat recorded 9 mentions for MoonLake Immunotherapeutics and 5 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.34 beat MoonLake Immunotherapeutics' score of 0.19 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bausch Health Companies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MoonLake Immunotherapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -5.07%. Bausch Health Companies' return on equity of -7.92% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -7.92% -7.76%
Bausch Health Companies -5.07%-2,370.91%4.88%

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Bausch Health Companies. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$0.75-53.00
Bausch Health Companies$8.97B0.28-$592M-$1.24-5.46

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MoonLake Immunotherapeutics beats Bausch Health Companies on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHC vs. The Competition

MetricBausch Health CompaniesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$2.48B$6.59B$4.89B$17.93B
Dividend YieldN/A2.72%44.82%3.42%
P/E Ratio-5.4610.16115.9722.52
Price / Sales0.28289.222,445.0610.55
Price / Cash0.9423.5932.5819.21
Price / Book-14.406.015.135.18
Net Income-$592M$136.18M$100.62M$972.86M
7 Day Performance-4.98%5.47%117.52%3.48%
1 Month Performance-22.09%8.60%124.72%8.34%
1 Year Performance-18.43%-1.61%134.78%27.36%

Bausch Health Companies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
2.5804 of 5 stars
$40.77
-2.3%
$74.46
+82.6%
+44.3%$2.60BN/A-54.3650Analyst Forecast
MRUS
Merus
2.7986 of 5 stars
$44.77
-2.4%
$56.33
+25.8%
+103.9%$2.63B$38.34M-16.16172
MRVI
Maravai LifeSciences
2.4057 of 5 stars
$10.70
+1.6%
$11.44
+7.0%
-15.4%$2.69B$288.95M-10.81650
JANX
Janux Therapeutics
3.4393 of 5 stars
$47.91
-4.2%
$69.50
+45.1%
+252.5%$2.48B$8.08M-39.2764Gap Up
RYTM
Rhythm Pharmaceuticals
3.081 of 5 stars
$40.38
+0.4%
$54.33
+34.6%
+126.4%$2.46B$91.93M-8.72226
DYN
Dyne Therapeutics
2.9946 of 5 stars
$28.16
+5.8%
$37.75
+34.1%
+102.0%$2.46BN/A-7.09141News Coverage
FOLD
Amicus Therapeutics
4.5344 of 5 stars
$9.33
+3.2%
$18.40
+97.2%
-19.6%$2.76B$399.36M-19.04517Gap Up
RNA
Avidity Biosciences
0.9677 of 5 stars
$28.91
+11.1%
$38.29
+32.4%
+172.6%$2.76B$9.56M-9.80253Earnings Report
ACAD
ACADIA Pharmaceuticals
4.0238 of 5 stars
$14.86
-2.1%
$28.94
+94.7%
-39.2%$2.46B$726.44M-1,484.52597
MOR
MorphoSys
0.5749 of 5 stars
$18.39
+1.8%
$11.78
-35.9%
+207.4%$2.77B$257.89M-5.28524Analyst Revision

Related Companies and Tools

This page (NYSE:BHC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners